-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
How to Invest in Obamacare-Era Healthcare
By Charles Sizemore -- In the complex post-Obamacare medical landscape, keep your investing simple. Stick with hospital stocks and avoid insurance stocks.
Bull’s Eye Report: Parexel (PRXL)
Parexel is one of the best opportunities in pharma right now.
Google Bets on Healthcare — You Should, Too
Google is aiming at helping humans live longer via a new venture, Calico -- another nod at just how lucrative the healthcare space should continue to be.
Trade of the Day: Tenet Healthcare (THC)
Upcoming political budget battles could cause significantly more problems, so holding bearish positions also makes sense.
3 Companies With a Headstart on Healthcare Reform
Lowering healthcare costs is a huge theme as the insurance exchanges are about to open, and these 3 companies have taken innovation into their own hands.
Trade of the Day: Cytokinetics (CYTK)
Though this pharmaceutical stock has been battered lately, both analysts and management are confident in the company's drug currently in the FDA pipeline.
4 Healthcare Investments to Make Before October
With open enrollment in state health insurance exchanges set to kick off on Oct. 1, it’s a good time to revisit the ways investors can play the opportunity.
3 Pharma Stocks Just Running in Place
Gobs of free cash flow doesn't mean a company is worth buying. Some companies, especially pharmaceuticals, just use cash to run in place.
This Top Sector Should Continue to Outperform
iShares Nasdaq Biotechnology (IBB) is trading within a powerful bull channel and just flashed a new buy signal.
The One Word You Should Know in Biopharma Right Now
Before you become impressed with a particular biopharma company's drug, you'll want to know this detail.
Biopharma’s 6 Biggest Deals: Were They Worth It?
With Amgen set to spend more than $10 billion to buy Onyx, investors are wondering if these super-sized biopharma acquisitions are worth it.
How to Profit From Every Biotech Buyout
Amgen's acquisition of Onyx underscores the fact that one simple biotech investment may also be the best one.
Grab These 3 Short-Term ETF Bargains While They Last
Leadership in the ETF circles has been focused on the regional and larger banks, gold miners, Internet, biotech and restaurant funds.
Will MannKind’s Luck Change the Second Time Around?
MannKind's diabetes drug, Afrezza, is back in Phase 3 trials and is showing similar promise. But can it clear the hump to approval ... unlike last time?
Pfizer & Merck: Dividend Winners or Duds?
Pfizer and Merck got addicted to Lipitor and Singulair, and now slumping sales of the former blockbusters have both companies scrambling for growth.
Merger Monday: Another Win for Healthcare Stocks
Omnicom and Saks made M&A ripples, but Elan's $6.7B sale to Perrigo fortifies the case for more deals in the healthcare sector.
Siemens Set to Fire CEO
The board of Siemens will make a decision Wednesday on whether or not to oust CEO Peter Loescher.
3 Perfect Biopharma Picks for Your Portfolio
If you want to play the volatile biopharma arena, choose carefully. Here are three hot stocks in the sector for different risk tolerances and time horizons.
Rest Easier With This Pair of Fundamentally Sound Biotechs
Biotechs can be lucrative but risky investments -- improve your chances by focusing on biotechs with quality fundamentals.
